DO-IN-2

Research use only, not for human use.

IDO-IN-2 is an IDO inhibitor extracted from patent WO/2015031295 A1, compound example 1.

IDO-IN-2 is a potent indoleamine 2,3-dioxygenase (IDO) inhibitor with IC50 of 0.068 uM.

PCC0208009 inhibits IDO1 activity in HeLa cells, with an IC50 value of 4.52 nM, but it does not change the enzyme activity in vitro, indicating that it acts as an indirect IDO1 inhibitor.PCC0208009 (0-200 nM; 48 hours) dose-dependently suppresses the IDO protein and mRNA expression induced by IFN-γ . Western Blot Analysis Cell Line:HeLa cells Concentration:0, 50, 100, 200 nM Incubation Time:48 hours Result:The IDO protein expression induced by IFN-γ was dose-dependently suppressed by PCC, which showed significant differences at 100 and 200?nM (P?

PCC0208009 (single oral gavage; 50 mg/kg) in adult male Sprague Dawley rats (180 g-200 g) is detected at 60, 120 and 240 min after drug administration in plasma and brain samples, and the highest concentrations of PCC0208009 in plasma and brainare observed at 60 min after administration. Concomitantly, the Kyn/Trp ratio decreases at 60, 120 and 240 min postdose, with the minimum level in the plasma and the brain seen at 60 min post-dose.PCC0208009(oral gavage; once; 12-50 mg/kg) in adult male Sprague Dawley rats (180 g-200 g) is detected at 30, 60 and 90min after administration to evaluate the antinociceptive effects of PCC0208009 on neuropathic pain. Animal Model:Adult male Sprague Dawley rats (180 g-200 g) Dosage:50 mg/kg Administration:Single oral gavage Result:The highest concentrations of PCC0208009 in plasma and brainwere observed at 60 min after administration. Animal Model:Adult male Sprague-Dawley rats bearing spinal nerve ligation (SNL)Dosage:12.5 mg/kg, 25 mg/kg, 50 mg/kg Administration:oral gavage; once Result:Showed the behavioral tests and the timelines.

IDO-IN-2 | IDO IN-2 | IDOIN-2 | IDO-IN2

Immunology/Inflammation

Antiviral

IDO

Cancer

——

1668565-74-9

497.65

C29H35N7O

>98% (HPLC)

DMSO : ≥ 31 mg/mL; 62.30 mM

Cc1ccc(cc1)NC(=O)Nc1c(ccc(c1)c1ccccc1c1n[nH]nn1)N(CC(C)C)CC(C)C

Urea, N-[4-[bis(2-methylpropyl)amino]-2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]-N'-(4-methylphenyl)-

(-20℃)

With Ice Pack

≥ 2 years